欧洲-话题@MedSci

#欧洲#

592篇内容 | 6072人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1339183, encodeId=28f21339183d6, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=第29届欧洲临床微生物学和传染病大会（ECCMID）：碳青霉烯类耐药菌的治疗选择, objectType=article, longId=164120, objectId=923e164120b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=923e164120b4, replyNumber=0, likeNumber=80, createdTime=2019-04-13, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=923e164120b4, moduleTitle=第29届欧洲临床微生物学和传染病大会（ECCMID）：碳青霉烯类耐药菌的治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=923e164120b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339182, encodeId=52ed133918266, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=DIABETOLOGIA：l-精氨酸对南亚和欧洲糖尿病前期患者能量代谢、骨骼肌和棕色脂肪组织的影响, objectType=article, longId=163671, objectId=a7931636e198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7931636e198, replyNumber=0, likeNumber=126, createdTime=2019-04-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7931636e198, moduleTitle=DIABETOLOGIA：l-精氨酸对南亚和欧洲糖尿病前期患者能量代谢、骨骼肌和棕色脂肪组织的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7931636e198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339181, encodeId=fb28133918107, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲EMA接受Takeda的α4β7整合素单抗Entyvio的上市申请，治疗溃疡性结肠炎, objectType=article, longId=163646, objectId=eaa016364694, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaa016364694, replyNumber=0, likeNumber=82, createdTime=2019-04-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaa016364694, moduleTitle=欧洲EMA接受Takeda的α4β7整合素单抗Entyvio的上市申请，治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaa016364694)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339180, encodeId=5b4e1339180b9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=DIABETOLOGIA：1989- 2013年25年间26个欧洲中心儿童1型糖尿病发病率趋势和周期性变化：多中心前瞻性登记研究, objectType=article, longId=163571, objectId=6d1b1635e1e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d1b1635e1e0, replyNumber=0, likeNumber=88, createdTime=2019-04-05, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d1b1635e1e0, moduleTitle=DIABETOLOGIA：1989- 2013年25年间26个欧洲中心儿童1型糖尿病发病率趋势和周期性变化：多中心前瞻性登记研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d1b1635e1e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339179, encodeId=578613391e962, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2019 欧洲共识建议：免疫球蛋白A血管炎的诊断和治疗, objectType=article, longId=163522, objectId=c9ce16352258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9ce16352258, replyNumber=0, likeNumber=16, createdTime=2019-04-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9ce16352258, moduleTitle=2019 欧洲共识建议：免疫球蛋白A血管炎的诊断和治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9ce16352258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339178, encodeId=ef9713391e8d8, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲批准Teva的CGRP单抗Ajovy用于治疗偏头痛, objectType=article, longId=163507, objectId=f81216350ee1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f81216350ee1, replyNumber=0, likeNumber=85, createdTime=2019-04-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f81216350ee1, moduleTitle=欧洲批准Teva的CGRP单抗Ajovy用于治疗偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f81216350ee1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339177, encodeId=69ab13391e741, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲CHMP推荐将Bluebird公司的基因疗法Zynteglo用于治疗输血依赖性β-地中海贫血, objectType=article, longId=163435, objectId=ce74163435a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce74163435a9, replyNumber=0, likeNumber=84, createdTime=2019-04-03, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce74163435a9, moduleTitle=欧洲CHMP推荐将Bluebird公司的基因疗法Zynteglo用于治疗输血依赖性β-地中海贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce74163435a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339176, encodeId=b81b13391e695, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=陆道培医疗团队参加第45届欧洲血液和骨髓移植学会年会, objectType=article, longId=163266, objectId=17e7163266ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17e7163266ab, replyNumber=0, likeNumber=104, createdTime=2019-03-31, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17e7163266ab, moduleTitle=陆道培医疗团队参加第45届欧洲血液和骨髓移植学会年会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17e7163266ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339175, encodeId=9cde13391e580, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2019 欧洲多学科指南：耳鸣的诊断，评估和治疗, objectType=article, longId=163064, objectId=670b163064ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=670b163064ba, replyNumber=0, likeNumber=17, createdTime=2019-03-28, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=670b163064ba, moduleTitle=2019 欧洲多学科指南：耳鸣的诊断，评估和治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=670b163064ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339174, encodeId=d48e13391e4c4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=第34届欧洲泌尿外科学会（EAU）大会：Atezolizumab对晚期转移性泌尿道癌有效, objectType=article, longId=162734, objectId=ed6f162e344b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed6f162e344b, replyNumber=0, likeNumber=71, createdTime=2019-03-23, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed6f162e344b, moduleTitle=第34届欧洲泌尿外科学会（EAU）大会：Atezolizumab对晚期转移性泌尿道癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed6f162e344b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339173, encodeId=63b613391e30d, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2019 欧洲专家共识声明：阿片类药物引起便秘的病理生理学和管理, objectType=article, longId=162003, objectId=42e216200324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42e216200324, replyNumber=0, likeNumber=13, createdTime=2019-03-11, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42e216200324, moduleTitle=2019 欧洲专家共识声明：阿片类药物引起便秘的病理生理学和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42e216200324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339172, encodeId=7e5713391e257, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=81, createdTime=2019-03-10, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339171, encodeId=1e1d13391e12e, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局的人类药物委员会（CHMP）推荐八种新药, objectType=article, longId=161661, objectId=d190161661ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d190161661ad, replyNumber=0, likeNumber=55, createdTime=2019-03-06, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d190161661ad, moduleTitle=欧洲药品管理局的人类药物委员会（CHMP）推荐八种新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d190161661ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339170, encodeId=c9e913391e0be, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Hansa Biopharma宣布欧洲药品管理局接受IDEFIRIX（imlifidase）用于高度敏感的肾移植患者的营销授权申请, objectType=article, longId=161543, objectId=416d16154305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=416d16154305, replyNumber=0, likeNumber=59, createdTime=2019-03-04, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=416d16154305, moduleTitle=Hansa Biopharma宣布欧洲药品管理局接受IDEFIRIX（imlifidase）用于高度敏感的肾移植患者的营销授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=416d16154305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339169, encodeId=59fa1339169fa, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=14, createdTime=2019-03-03, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339168, encodeId=e86913391680f, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=武田、微软和欧洲罕见病组织发布报告为罕见病患者提供行动建议, objectType=article, longId=161522, objectId=6cc0161522fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc0161522fc, replyNumber=0, likeNumber=77, createdTime=2019-03-03, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc0161522fc, moduleTitle=武田、微软和欧洲罕见病组织发布报告为罕见病患者提供行动建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc0161522fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339167, encodeId=8f12133916e32, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Eur J Heart Fail：欧洲利尿剂治疗心衰声明：优化使用利尿剂，根据尿钠判断利尿剂抵抗, objectType=article, longId=161374, objectId=f42c1613e463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f42c1613e463, replyNumber=0, likeNumber=66, createdTime=2019-03-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f42c1613e463, moduleTitle=Eur J Heart Fail：欧洲利尿剂治疗心衰声明：优化使用利尿剂，根据尿钠判断利尿剂抵抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f42c1613e463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339166, encodeId=78a5133916645, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果, objectType=article, longId=161336, objectId=efde161336db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efde161336db, replyNumber=0, likeNumber=60, createdTime=2019-03-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efde161336db, moduleTitle=第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efde161336db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339165, encodeId=86211339165e9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局将规范基因和细胞疗法发布临床试验指南草案, objectType=article, longId=161129, objectId=9789161129cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9789161129cc, replyNumber=0, likeNumber=63, createdTime=2019-02-27, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9789161129cc, moduleTitle=欧洲药品管理局将规范基因和细胞疗法发布临床试验指南草案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9789161129cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339164, encodeId=6aaf1339164db, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Rizmoic获得欧洲委员会的营销许可，用于治疗阿片类药物引起的成人便秘, objectType=article, longId=161016, objectId=c2c016101643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2c016101643, replyNumber=0, likeNumber=90, createdTime=2019-02-26, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2c016101643, moduleTitle=Rizmoic获得欧洲委员会的营销许可，用于治疗阿片类药物引起的成人便秘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2c016101643)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

第29届欧洲临床微生物学和传染病大会（ECCMID）：碳青霉烯类耐药菌的治疗选择

2019-04-13

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

DIABETOLOGIA：l-精氨酸对南亚和欧洲糖尿病前期患者能量代谢、骨骼肌和棕色脂肪组织的影响

2019-04-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲EMA接受Takeda的α4β7整合素单抗Entyvio的上市申请，治疗溃疡性结肠炎

2019-04-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

DIABETOLOGIA：1989- 2013年25年间26个欧洲中心儿童1型糖尿病发病率趋势和周期性变化：多中心前瞻性登记研究

2019-04-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2019 欧洲共识建议：免疫球蛋白A血管炎的诊断和治疗

2019-04-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲批准Teva的CGRP单抗Ajovy用于治疗偏头痛

2019-04-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲CHMP推荐将Bluebird公司的基因疗法Zynteglo用于治疗输血依赖性β-地中海贫血

2019-04-03

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

陆道培医疗团队参加第45届欧洲血液和骨髓移植学会年会

2019-03-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2019 欧洲多学科指南：耳鸣的诊断，评估和治疗

2019-03-28

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

第34届欧洲泌尿外科学会（EAU）大会：Atezolizumab对晚期转移性泌尿道癌有效

2019-03-23

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2019 欧洲专家共识声明：阿片类药物引起便秘的病理生理学和管理

2019-03-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-03-10

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局的人类药物委员会（CHMP）推荐八种新药

2019-03-06

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Hansa Biopharma宣布欧洲药品管理局接受IDEFIRIX（imlifidase）用于高度敏感的肾移植患者的营销授权申请

2019-03-04

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

武田、微软和欧洲罕见病组织发布报告为罕见病患者提供行动建议

2019-03-03

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Eur J Heart Fail：欧洲利尿剂治疗心衰声明：优化使用利尿剂，根据尿钠判断利尿剂抵抗

2019-03-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果

2019-03-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局将规范基因和细胞疗法发布临床试验指南草案

2019-02-27

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Rizmoic获得欧洲委员会的营销许可，用于治疗阿片类药物引起的成人便秘

2019-02-26

科室
- - 订阅+
  - 更多科室
工具
服务